IN2015DN03331A - - Google Patents

Download PDF

Info

Publication number
IN2015DN03331A
IN2015DN03331A IN3331DEN2015A IN2015DN03331A IN 2015DN03331 A IN2015DN03331 A IN 2015DN03331A IN 3331DEN2015 A IN3331DEN2015 A IN 3331DEN2015A IN 2015DN03331 A IN2015DN03331 A IN 2015DN03331A
Authority
IN
India
Prior art keywords
sina
betahydroxysteroid
dchydrogenase
isd1
beta
Prior art date
Application number
Inventor
Antón Ana Isabel Jiménez
Angela Sesto Yague
GÓMEZ Ma Concepción JIMÉNEZ
Original Assignee
Sylentis Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sylentis Sa filed Critical Sylentis Sa
Publication of IN2015DN03331A publication Critical patent/IN2015DN03331A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y101/00—Oxidoreductases acting on the CH-OH group of donors (1.1)
    • C12Y101/01—Oxidoreductases acting on the CH-OH group of donors (1.1) with NAD+ or NADP+ as acceptor (1.1.1)
    • C12Y101/01146—11-Beta-hydroxysteroid dehydrogenase (1.1.1.146)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.

Abstract

The invention relates to siNA compositions and methods for the treatment of eye conditions wherein the siNA compound capable of inhibiting the expression of 11 betahydroxysteroid dchydrogenase (11 beta-I ISD1).
IN3331DEN2015 2005-10-25 2006-10-25 IN2015DN03331A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0521716.1A GB0521716D0 (en) 2005-10-25 2005-10-25 Modulation of 11beta-hydroxysteriod dehydrogenase 1 expression for the treatment of ocular diseases
PCT/GB2006/050352 WO2007049074A2 (en) 2005-10-25 2006-10-25 Modulation of 11beta-hydroxysteroid dehydrogenase 1 expression for the treatment of ocular diseases

Publications (1)

Publication Number Publication Date
IN2015DN03331A true IN2015DN03331A (en) 2015-10-23

Family

ID=35458653

Family Applications (1)

Application Number Title Priority Date Filing Date
IN3331DEN2015 IN2015DN03331A (en) 2005-10-25 2006-10-25

Country Status (13)

Country Link
US (1) US8188057B2 (en)
EP (2) EP1941037B1 (en)
JP (2) JP5398262B2 (en)
CN (1) CN101346467B (en)
AU (1) AU2006307690B2 (en)
CA (1) CA2627272C (en)
ES (1) ES2403305T3 (en)
GB (1) GB0521716D0 (en)
HK (1) HK1120830A1 (en)
IN (1) IN2015DN03331A (en)
MX (1) MX2008005409A (en)
RU (1) RU2420582C2 (en)
WO (1) WO2007049074A2 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070049543A1 (en) * 2001-05-18 2007-03-01 Sirna Therapeutics, Inc. RNA interference mediated inhibition of 11 beta-hydroxysteroid dehydrogenase-1 (11 beta-HSD-1) gene expression using short interfering nucleic acid siNA
WO2009073460A2 (en) * 2007-12-03 2009-06-11 Bausch & Lomb Incorporated Inhibition of 11 beta-hydroxysteroid dehydrogenase type 1 for ocular neuroprotection
CN101976979A (en) * 2010-10-25 2011-02-16 北京印刷学院 Parabolic cylinder concentrating semi-cylinder closed cavity lighting solar generation device
CN101969282A (en) * 2010-10-25 2011-02-09 北京印刷学院 Parabolic cylindrical surface light concentration concave closed cavity light collection solar power generation device
EP3043827B1 (en) * 2013-09-13 2019-07-03 Ionis Pharmaceuticals, Inc. Modulators of complement factor b
MA44908A (en) * 2015-09-08 2018-07-18 Sylentis Sau ARNSI MOLECULES AND THEIR USE IN PROCESSES AND COMPOSITIONS TO INHIBIT NRARP GENE EXPRESSION
CN106702003B (en) * 2017-02-28 2021-02-12 固安博健生物技术有限公司 Application of HSDL1 in diagnosis and treatment of osteosarcoma
CN109022436B (en) * 2018-06-07 2021-04-09 深圳市疾病预防控制中心（深圳市卫生检验中心、深圳市预防医学研究所） shRNA recombinant vector construction and application for specifically inhibiting 3 beta-HSD gene expression
JP6617191B1 (en) * 2018-12-03 2019-12-11 三井金属鉱業株式会社 Method and apparatus for separating or analyzing target components in a solution

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4343794A (en) * 1980-05-06 1982-08-10 Mt. Sinai Method of reducing intraocular pressure with salts of vanadic acid
US4652586A (en) * 1980-11-07 1987-03-24 The General Hospital Corporation Selective beta-2 adrenergic antagonists for the treatment of glaucoma
US4617299A (en) * 1983-12-19 1986-10-14 Knepper Paul A Method for the prevention of ocular hypertension, treatment of glaucoma and treatment of ocular hypertension
US5242943A (en) * 1984-03-28 1993-09-07 William J. Louis 3-aminopropoxyphenyl derivatives, their preparation and pharmaceutical compositions containing them
US4812448A (en) * 1984-10-22 1989-03-14 Knepper Paul A Method for the prevention of ocular hypertension, treatment of glaucoma and treatment of ocular hypertension
US4757089A (en) * 1985-06-14 1988-07-12 Massachusetts Eye And Ear Infirmary Increasing aqueous humor outflow
US5075323A (en) * 1988-08-24 1991-12-24 Aktiebolaget Hassle Compounds including omeprazole in the treatment of glaucoma
US5260059A (en) * 1989-04-14 1993-11-09 The State Of Oregon Acting By And Through The State Board Of Higher Education On Behalf Of Oregon Health Sciences University Treatment of open-angle glaucoma by modulation matrix metalloproteinases and their inhibitor
US6372249B1 (en) * 1991-12-16 2002-04-16 Baylor College Of Medicine Senscent cell-derived inhibitors of DNA synthesis
US5464866A (en) * 1992-08-17 1995-11-07 Alcon Laboratories, Inc. Substituted hydrindanes for the treatment of angiogenesis-dependent diseases
US5545626A (en) * 1994-01-19 1996-08-13 The Trustees Of Columbia University In The City Of New York Method of treating glaucoma with oligonucleotides
US5585401A (en) * 1994-12-09 1996-12-17 The Reents Of The University Of California Method for enhancing outflow of aqueous humor in treatment of glaucoma
US20020055536A1 (en) * 1996-09-26 2002-05-09 Dewitte Robert S. System and method for structure-based drug design that includes accurate prediction of binding free energy
US6489307B1 (en) * 1998-09-14 2002-12-03 University Of Florida Antisense compositions targeted to β1-adrenoceptor-specific mRNA and methods of use
CA2361201A1 (en) * 1999-01-28 2000-08-03 Medical College Of Georgia Research Institute, Inc. Composition and method for in vivo and in vitro attenuation of gene expression using double stranded rna
US6365576B1 (en) * 1999-06-24 2002-04-02 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Method for inhibiting herpes infection
CZ308053B6 (en) * 2000-12-01 2019-11-27 Max Planck Gesellschaft Isolated double-stranded RNA molecule, process for producing it and its use
US20020165158A1 (en) * 2001-03-27 2002-11-07 King George L. Methods of modulating angiogenesis
US20040209832A1 (en) * 2001-11-30 2004-10-21 Mcswiggen James RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA)
US20070049543A1 (en) * 2001-05-18 2007-03-01 Sirna Therapeutics, Inc. RNA interference mediated inhibition of 11 beta-hydroxysteroid dehydrogenase-1 (11 beta-HSD-1) gene expression using short interfering nucleic acid siNA
US20050148530A1 (en) * 2002-02-20 2005-07-07 Sirna Therapeutics, Inc. RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA)
EP1587574A4 (en) * 2001-12-21 2009-03-18 Rhode Island Hospital SELECTIVE 11b-HSD INHIBITORS AND METHODS FOR USE THEREOF
US7294504B1 (en) 2001-12-27 2007-11-13 Allele Biotechnology & Pharmaceuticals, Inc. Methods and compositions for DNA mediated gene silencing
GB2406568B (en) 2002-02-20 2005-09-28 Sirna Therapeutics Inc RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
AU2003207708A1 (en) 2002-02-20 2003-09-09 Sirna Therapeutics, Inc. Rna interference mediated inhibition of map kinase genes
EP1495121A2 (en) 2002-04-18 2005-01-12 Lynkeus Biotech GmbH Means and methods for the specific inhibition of genes in cells and tissue of the cns and/or eye
US20040115641A1 (en) * 2002-12-11 2004-06-17 Isis Pharmaceuticals Inc. Modulation of ROCK 1 expression
JP2005533504A (en) 2002-07-24 2005-11-10 イミューソル インコーポレイテッド Single promoter system for production of siRNA expression cassette and expression library using polymerase primer hairpin linker
AU2003254151B2 (en) 2002-07-24 2006-08-31 Immusol Incorporated Novel siRNA libraries and their production and use
DE60310944T3 (en) 2002-08-05 2017-08-03 Silence Therapeutics Gmbh OTHER NEW FORMS OF INTERFERING RNS MOLECULES
CA2500224C (en) * 2002-09-25 2015-04-28 University Of Massachusetts In vivo gene silencing by chemically modified and stable sirna
AU2003291678B2 (en) * 2002-11-01 2009-01-15 The Trustees Of The University Of Pennsylvania Compositions and methods for siRNA inhibition of HIF-1 alpha
DE10322662A1 (en) 2002-11-06 2004-10-07 Grünenthal GmbH New DNA type 10-23 enzyme, useful for treating e.g. pain, and related short interfering RNA, directed against the vanillin receptor or picorna viruses, contains specific nucleotide modifications for improved stability
US7250496B2 (en) * 2002-11-14 2007-07-31 Rosetta Genomics Ltd. Bioinformatically detectable group of novel regulatory genes and uses thereof
JP2006507841A (en) * 2002-11-14 2006-03-09 ダーマコン， インコーポレイテッド Functional and ultrafunctional siRNA
US20060257851A1 (en) * 2002-11-26 2006-11-16 Itzhak Bentwich Bioinformatically detectable group of novel viral regulatory genes and uses thereof
TW200503994A (en) * 2003-01-24 2005-02-01 Novartis Ag Organic compounds
US20040167090A1 (en) * 2003-02-21 2004-08-26 Monahan Sean D. Covalent modification of RNA for in vitro and in vivo delivery
GB0307206D0 (en) * 2003-03-28 2003-04-30 Axordia Ltd Hyperproliferation
US20040198640A1 (en) * 2003-04-02 2004-10-07 Dharmacon, Inc. Stabilized polynucleotides for use in RNA interference
US7462602B2 (en) * 2003-05-01 2008-12-09 University Of Florida Research Foundation, Inc. Anti-scarring ribozymes and methods
US20040224405A1 (en) * 2003-05-06 2004-11-11 Dharmacon Inc. siRNA induced systemic gene silencing in mammalian systems
DE10322539A1 (en) 2003-05-19 2004-12-09 Siemens Ag Method for establishing a communication link and communication system
WO2005044976A2 (en) 2003-06-20 2005-05-19 Isis Pharmaceuticals, Inc. Oligomeric compounds for use in gene modulation
US20050197364A1 (en) 2003-10-07 2005-09-08 Kelly Michael G. Amide compounds as ion channel ligands and uses thereof
WO2005045037A2 (en) 2003-10-23 2005-05-19 Sirna Therapeutics, Inc. RNA INTERFERENCE MEDIATED INHIBITION OF 5-ALPHA REDUCTASE AND ANDROGEN RECEPTOR GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
KR20050039573A (en) 2003-10-23 2005-04-29 주식회사 태평양 Thiourea derivative-containing pharmaceutical composition having improved solubility and bioavailability
US20050208658A1 (en) * 2003-11-21 2005-09-22 The University Of Maryland RNA interference mediated inhibition of 11beta hydroxysteriod dehydrogenase-1 (11beta HSD-1) gene expression
US7544803B2 (en) * 2004-01-23 2009-06-09 Amgen Inc. Vanilloid receptor ligands and their use in treatments
WO2005076998A2 (en) 2004-02-05 2005-08-25 Intradigm Corporation Rnai therapeutics for treatment of eye neovascularization diseases
GB0403600D0 (en) 2004-02-18 2004-03-24 Trinity College Dublin Methods and reagents for treating disease
EP1735009A4 (en) * 2004-03-12 2011-03-30 Alnylam Pharmaceuticals Inc iRNA AGENTS TARGETING VEGF
KR101147147B1 (en) * 2004-04-01 2012-05-25 머크 샤프 앤드 돔 코포레이션 Modified polynucleotides for reducing off-target effects in rna interference
WO2005117938A2 (en) * 2004-04-13 2005-12-15 Regents Of The University Of Minnesota Methods of treating ocular conditions
JP2008504280A (en) * 2004-06-24 2008-02-14 インサイト・コーポレイション 2-methylpropanamide and its pharmaceutical use
EP2990410A1 (en) * 2004-08-10 2016-03-02 Alnylam Pharmaceuticals Inc. Chemically modified oligonucleotides
SI1781787T1 (en) * 2004-08-23 2017-08-31 Sylentis S.A.U. Treatment of eye disorders characterized by an elevated intraocular pressure by sirnas
TW200639252A (en) 2005-02-01 2006-11-16 Alcon Inc RNAi-mediated inhibition of ocular hypertension targets
US7947660B2 (en) 2005-03-11 2011-05-24 Alcon, Inc. RNAi-mediated inhibition of frizzled related protein-1 for treatment of glaucoma

Also Published As

Publication number Publication date
AU2006307690B2 (en) 2012-07-12
EP2354229A3 (en) 2012-12-05
JP2013176395A (en) 2013-09-09
WO2007049074A3 (en) 2007-08-02
HK1120830A1 (en) 2009-04-09
CN101346467A (en) 2009-01-14
MX2008005409A (en) 2008-11-26
US20110160277A1 (en) 2011-06-30
CA2627272A1 (en) 2007-05-03
JP5398262B2 (en) 2014-01-29
EP1941037A2 (en) 2008-07-09
EP2354229A2 (en) 2011-08-10
CA2627272C (en) 2015-12-01
RU2420582C2 (en) 2011-06-10
AU2006307690A1 (en) 2007-05-03
WO2007049074A2 (en) 2007-05-03
US8188057B2 (en) 2012-05-29
CN101346467B (en) 2013-03-13
EP1941037B1 (en) 2013-01-16
ES2403305T3 (en) 2013-05-17
GB0521716D0 (en) 2005-11-30
RU2008120702A (en) 2009-12-10
JP2009513617A (en) 2009-04-02

Similar Documents

Publication Publication Date Title
IN2015DN03331A (en)
MX2009000657A (en) Compositions and methods for the treatment of mucositis.
PT1984357E (en) 2,4-pyrimidinediamine compounds for treating or preventing autoimmune diseases
TW200637866A (en) Amino-imidazolones for the inhibition of β-secretase
TW200640924A (en) VEGF-R2 inhibitors and methods
WO2007059154A3 (en) Treatment of cancers with acquired resistance to kit inhibitors
PH12015500550A1 (en) Anti-notch1 nrr antibodies and methods using same
WO2007092622A3 (en) Compositions and methods for treating bone
UA101478C2 (en) Compounds useful as inhibitors of raf protein kinase
UA86599C2 (en) Substituted benzimidazole-, benztriazole- and benzimidazolone-о-glucosides
MY153424A (en) Modulators of indoleamine 2,3-dioxygenase and methods of using the same
WO2007038610A3 (en) Use of natural products for treatment of neurological disorders
MX2009007075A (en) Methods of use for cyclopamine analogs.
MX349137B (en) Methods and compositions for the treatment of persistent infections and cancer by inhibiting the programmed cell death 1 (pd-1) pathway.
WO2007026251A3 (en) Use of dual c-kit/fgfr3 inhibitors for treating multiple myeloma
TW200639166A (en) Amino-pyridines as inhibitors of β-secretase
WO2008070129A3 (en) Compositions and methods for the treatment of inflammatory disease
TW200724140A (en) Hydantoin compounds
IL190730A0 (en) Potassium channel inhibitors
UA86119C2 (en) Amide prodrug of gemcitabine, compositions and use thereof
WO2010053573A3 (en) Screen for inhibitors of filovirus and uses therefor
SG158091A1 (en) Imidazoazepinone compounds
WO2008073332A3 (en) Creatine compositions for skin treatment
TW200613308A (en) Cyclobutanetetracarboxylate compound and preparation method thereof
TW200738244A (en) 20-Alkyl, gemini vitamin D3 compounds and methods of use thereof